Skip to main content

Table 2 Meta-analysis for OS

From: Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

Comparison Studies HR (95%CI) PA value I2 PH-value Model
Overall 10 2.12 (1.61,2.79) < 0.001 72.0 < 0.001 R
Subgroup       
Country Asian 7 2.56 (1.90, 3.44) < 0.001 54.5 0.040 R
Non-Asian 3 1.39 (1.14, 1.70) 0.001 0.0 0.634 F
Sample size < 200 4 2.08 (1.46, 2.96) < 0.001 43.3 0.152 F
> 200 6 2.16 (1.44, 3.22) < 0.001 81.2 0.000 R
Cut-off < 600 4 2.24 (1.54, 3.23) < 0.001 45.2 0.140 F
> 600 6 2.05 (1.39, 3.04) < 0.001 80.5 < 0.001 R
HR source M 8 2.34 (1.70,3.21) 0.000 77.1 0.001 R
U 2 1.42 (1.10,1.84) 0.008 0.0 0.357 F
Cancer type Cervical cancer 3 2.34 (1.55, 3.50) < 0.001 0.0 0.431 F
Ovarian cancer 3 2.33 (1.08, 5.04) 0.032 81.7 0.004 R
Breast cancer 4 1.98 (1.31, 2.99) 0.001 82.8 0.001 R
TNBC 3 2.16 (1.31,3.56) 0.002 78.7 0.009 R
Other BC type 3 1.79 (1.29, 2.49) 0.005 0.0 0.863 F
Follow-up < 48 m 7 2.42 (1.66, 3.52) < 0.001 70.9 0.002 R
> 48 m 2 1.98 (1.16, 3.37) 0.012 72.0 0.059 R
Unclear 1 1.34 (1.00, 1.79) 0.047 R
  1. TNBC triple-negative breast cancer, OS overall survival, m month, HR hazard ratio, CI confidence interval, M multivariate, U univariate, R random-effects, F fixed-effects;PAP value for association; PH, P value for heterogeneity